Cohance Lifesciences Financial Results
- Market cap
- ₹17,384 crore
- P/E
- 163.6
- P/B
- 4.44
- ROE
- 4.7%
- Dividend yield
- 1.20%
For the year ended Mar 2020, Cohance Lifesciences reported revenue of ₹834 crore and net profit of ₹317 crore, against ₹1,010 crore and ₹362 crore a year earlier.
Cohance Lifesciences annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | 834 | 1,010 | 1,320 | 1,331 | 1,034 | 2,526 | 2,204 | 2,142 |
| Expenses | 449 | 569 | 741 | 757 | 625 | 1,696 | 1,769 | 1,825 |
| Operating profit | 385 | 440 | 579 | 574 | 409 | 830 | 435 | 316 |
| Operating margin % | 46% | 44% | 44% | 43% | 40% | 33% | 20% | 15% |
| Other income | 18 | 14 | 92 | 46 | 58 | 17 | -6 | 11 |
| Interest | 23 | 9 | 6 | 13 | 7 | 38 | 35 | 34 |
| Depreciation | 24 | 32 | 39 | 48 | 55 | 167 | 187 | 192 |
| Profit before tax | 356 | 414 | 626 | 560 | 406 | 643 | 207 | 101 |
| Tax % | 25% | 25% | 34% | 27% | 26% | 25% | 27% | 42% |
| Net profit | 317 | 362 | 454 | 411 | 300 | 484 | 150 | 59 |
| EPS (₹) | 12.45 | 14.23 | 0.00 | 16.16 | 11.80 | 19.14 | 4.68 | 2.78 |
| Dividend payout % | — | — | — | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Cohance Lifesciences financial results — frequently asked questions
What is Cohance Lifesciences' annual revenue and net profit?
For the financial year ended Mar 2020, Cohance Lifesciences' revenue was ₹834 crore and net profit ₹317 crore; net profit fell 12.43% from ₹362 crore in Mar 2021.
How fast has Cohance Lifesciences grown over three years?
From Mar 2023 to Mar 2020, Cohance Lifesciences' revenue grew at a compound annual rate of -14.4% and net profit at -8.3%. Past growth does not indicate future results.
What is the EPS of Cohance Lifesciences?
Annual EPS for Mar 2020 was ₹12.45.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Cohance Lifesciences With ATS
Track COHANCE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.